This study aimed to evaluate the efficacy, survival and safety of carboplatin based first-line chemotherapy in advanced breast cancer of HER2-low and HER2-zero, to explore whether carboplatin based first-line therapy could improve outcomes in HER2-low patients, and to analyze the potential factors affecting efficacy and prognosis. The gene discussed is ERBB2; the disease is breast cancer.